In the quest to find therapies for multi-drug resistant HIV, researchers have zeroed in on raltegravir. The latest data indicates this potent agent provides the highest reported virologic suppression rate among multi-drug resistant patients. Is raltegravir proving more effective than antiretrovirals? Does it carry any prominent side effects? Dr. Roy Steigbigel, professor of medicine and pathology, molecular genetics and microbiology, and pharmacological sciences, and founding director of the Comprehensive AIDS Center at the State University of New York at Stony Brook, details his New England Journal of Medicine research on raltegravir therapy for multi-drug resistant HIV with host Dr. Mark Nolan Hill.
Raltegravir Therapy for Multi-Drug Resistant HIV
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
In the quest to find therapies for multi-drug resistant HIV, researchers have zeroed in on raltegravir. The latest data indicates this potent agent provides the highest reported virologic suppression rate among multi-drug resistant patients. Is raltegravir proving more effective than antiretrovirals? Does it carry any prominent side effects? Dr. Roy Steigbigel, professor of medicine and pathology, molecular genetics and microbiology, and pharmacological sciences, and founding director of the Comprehensive AIDS Center at the State University of New York at Stony Brook, details his New England Journal of Medicine research on raltegravir therapy for multi-drug resistant HIV with host Dr. Mark Nolan Hill.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
A Practical Guide to Prescribing in HF
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?